{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-021541","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2026-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.977226+00:00","generated_at":"2026-05-15T23:00:41.324265+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"Ocular Therapeutix makes slides with SOL-1 Phase 3 results for AXPAXLI in wet AMD available at Macula Society","bullets":["Slides from 49th Macula Society Annual Meeting on Feb 27, 2026 posted on investor website.","Presentation covers detailed results from SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI).","AXPAXLI is being developed for treatment of wet age-related macular degeneration (wet AMD).","Filing does not disclose the actual trial outcomes or numerical results."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-021541","json":"https://secwatch.observer/filing/0001104659-26-021541.json","markdown":"https://secwatch.observer/filing/0001104659-26-021541.md","text":"https://secwatch.observer/filing/0001104659-26-021541.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465926021541/0001104659-26-021541-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465926021541/tm267471d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:00:41.324265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}